Robert F. Mattrey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert F. Mattrey has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Flemming Forsberg
Department of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107, USA
4 shared publications - John R. Eisenbrey
Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA
4 shared publications - Haydee Ojeda-Fournier
Breast Imaging Division, Department of Radiology, UC San Diego Health, Koman Family Outpatient Pavilion, 9400 Campus Point Dr, La Jolla, CA 92037
3 shared publications - Jacques Lux
Department of Radiology, Translational Research in Ultrasound Theranostics (TRUST) Program University of Texas Southwestern Medical Center Dallas Texas USA
3 shared publications Alexander M. Vezeridis
Department of Radiology, University of California, San Diego, La Jolla, CA 92093, USA
2 shared publicationsAlexander Sevrukov
Department of Radiology, Thomas Jefferson University, 763H Main Building, 132 South 10th Street, Philadelphia, PA 19107
2 shared publications
Latest Publications
- 1 October 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (1) , e230727
Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial
Background Contrast-enhanced (CE) US has been studied for use in the detection of residual viable hepatocellular carcinoma (HCC) after locoregional therapy, but multicenter data are lacking. Purpose To compare two-dimensional (2D) and three-dimensional (3D) CE US diagnostic performance with that of CE MRI or CT, the current clinical standard, in the detection of residual viable HCC after transarterial chemoembolization (TACE) in a prospective multicenter trial. Materials and Methods Participants aged at least 21 years with US-visible HCC scheduled for TACE were consecutively enrolled at one of three participating academic medical centers from May 2016 to March 2022. Each underwent baseline 2D and 3D CE US before TACE, 2D and 3D CE US 1-2 weeks and/or 4-6 weeks after TACE, and CE MRI or CT 4-6 weeks after TACE. CE US and CE MRI or CT were evaluated by three fellowship-trained radiologists for the presence or absence of viable tumors and were compared with reference standards of pathology (18%), angiography on re-treatment after identification of residual disease at 1-2-month follow-up imaging (31%), 4-8-month CE MRI or CT (42%), or short-term (approximately 1-2 months) CE MRI or CT if clinically decompensated and estimated viability was greater than 50% at imaging (9%). Diagnostic performance criteria, including sensitivity and specificity, were obtained for each modality and time point with generalized estimating equation analysis. Results A total of 132 participants were included (mean age, 64 years ± 7 [SD], 87 male). Sensitivity of 2D CE US 4-6 weeks after TACE was 91% (95% CI: 84, 95), which was higher than that of CE MRI or CT (68%; 95% CI: 58, 76; P < .001). Sensitivity of 3D CE US 4-6 weeks after TACE was 89% (95% CI: 81, 94), which was higher than that of CE MRI or CT (P < .001), with no evidence of a difference from 2D CE US (P = .22). CE MRI or CT had 85% (95% CI: 76, 91) specificity, higher than that of 4-6-week 2D and 3D CE US (70% [95% CI: 56, 80] and 67% [95% CI: 53, 78], respectively; P = .046 and P = .023, respectively). No evidence of differences in any diagnostic criteria were observed between 1-2-week and 4-6-week 2D CE US (P > .21). Conclusion The 2D and 3D CE US examinations 4-6 weeks after TACE revealed higher sensitivity in the detection of residual HCC than CE MRI or CT, albeit with lower specificity. Importantly, CE US performance was independent of follow-up time. Clinical trial registration no. NCT02764801 © RSNA, 2023 Supplemental material is available for this article.
- 1 October 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (1) , e230727
Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial
Background Contrast-enhanced (CE) US has been studied for use in the detection of residual viable hepatocellular carcinoma (HCC) after locoregional therapy, but multicenter data are lacking. Purpose To compare two-dimensional (2D) and three-dimensional (3D) CE US diagnostic performance with that of CE MRI or CT, the current clinical standard, in the detection of residual viable HCC after transarterial chemoembolization (TACE) in a prospective multicenter trial. Materials and Methods Participants aged at least 21 years with US-visible HCC scheduled for TACE were consecutively enrolled at one of three participating academic medical centers from May 2016 to March 2022. Each underwent baseline 2D and 3D CE US before TACE, 2D and 3D CE US 1-2 weeks and/or 4-6 weeks after TACE, and CE MRI or CT 4-6 weeks after TACE. CE US and CE MRI or CT were evaluated by three fellowship-trained radiologists for the presence or absence of viable tumors and were compared with reference standards of pathology (18%), angiography on re-treatment after identification of residual disease at 1-2-month follow-up imaging (31%), 4-8-month CE MRI or CT (42%), or short-term (approximately 1-2 months) CE MRI or CT if clinically decompensated and estimated viability was greater than 50% at imaging (9%). Diagnostic performance criteria, including sensitivity and specificity, were obtained for each modality and time point with generalized estimating equation analysis. Results A total of 132 participants were included (mean age, 64 years ± 7 [SD], 87 male). Sensitivity of 2D CE US 4-6 weeks after TACE was 91% (95% CI: 84, 95), which was higher than that of CE MRI or CT (68%; 95% CI: 58, 76; P < .001). Sensitivity of 3D CE US 4-6 weeks after TACE was 89% (95% CI: 81, 94), which was higher than that of CE MRI or CT (P < .001), with no evidence of a difference from 2D CE US (P = .22). CE MRI or CT had 85% (95% CI: 76, 91) specificity, higher than that of 4-6-week 2D and 3D CE US (70% [95% CI: 56, 80] and 67% [95% CI: 53, 78], respectively; P = .046 and P = .023, respectively). No evidence of differences in any diagnostic criteria were observed between 1-2-week and 4-6-week 2D CE US (P > .21). Conclusion The 2D and 3D CE US examinations 4-6 weeks after TACE revealed higher sensitivity in the detection of residual HCC than CE MRI or CT, albeit with lower specificity. Importantly, CE US performance was independent of follow-up time. Clinical trial registration no. NCT02764801 © RSNA, 2023 Supplemental material is available for this article.
- 1 October 2021
- Published by Acoustical Society of America (ASA) in The Journal of the Acoustical Society of America
- Vol. 150 (4_Suppleme) , A28
A novel microbubble platform for cancer immunotherapy
The innate immune sensor cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS-STING) has recently emerged as a potential therapeutic target to boost antitumor immune responses. However, STING is a cytoplasmic protein, and its natural activator cGAMP is a negatively charged dinucleotide that is difficult to deliver intracellularly. We have developed a new platform called Microbubble-assisted UltraSound (US)-guided Immunotherapy of Cancer (MUSIC) to activate STING with spatio-temporal control to treat cancer. MUSIC showed greater STING activation compared to cGAMP alone in vitro. In murine models,MUSIC showed dramatic tumor growth inhibition and increased survival in both syngeneic breast cancer models. The absence of antitumor immune responses in STING-/- mice shows that MUSIC action is STING-dependent. Furthermore, 6/10 MUSIC-treated mice were tumor-free versus 2/10 cGAMP-treated mice. All the rechallenged MUSIC-treated mice remained tumor-free 30 days after rechallenge. MUSIC also resulted in a 7-fold decrease in metastatic burden when compared to cGAMP alone. In summary, MUSIC showed efficient STING activation invitro. In addition, local MUSIC treatment of primary tumors produced systemic antitumor immune responses in vivo as well as anticancer immune memory preventing tumor growth upon rechallenge. We are now exploring the use of nanobubbles for systemic administration. [Work supported by CPRIT Grants RR150010 and RP190233. R.F.M. is a CPRIT Established Investigator.]
- 1 October 2021
- Published by Acoustical Society of America (ASA) in The Journal of the Acoustical Society of America
- Vol. 150 (4_Suppleme) , A28
A novel microbubble platform for cancer immunotherapy
The innate immune sensor cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS-STING) has recently emerged as a potential therapeutic target to boost antitumor immune responses. However, STING is a cytoplasmic protein, and its natural activator cGAMP is a negatively charged dinucleotide that is difficult to deliver intracellularly. We have developed a new platform called Microbubble-assisted UltraSound (US)-guided Immunotherapy of Cancer (MUSIC) to activate STING with spatio-temporal control to treat cancer. MUSIC showed greater STING activation compared to cGAMP alone in vitro. In murine models,MUSIC showed dramatic tumor growth inhibition and increased survival in both syngeneic breast cancer models. The absence of antitumor immune responses in STING-/- mice shows that MUSIC action is STING-dependent. Furthermore, 6/10 MUSIC-treated mice were tumor-free versus 2/10 cGAMP-treated mice. All the rechallenged MUSIC-treated mice remained tumor-free 30 days after rechallenge. MUSIC also resulted in a 7-fold decrease in metastatic burden when compared to cGAMP alone. In summary, MUSIC showed efficient STING activation invitro. In addition, local MUSIC treatment of primary tumors produced systemic antitumor immune responses in vivo as well as anticancer immune memory preventing tumor growth upon rechallenge. We are now exploring the use of nanobubbles for systemic administration. [Work supported by CPRIT Grants RR150010 and RP190233. R.F.M. is a CPRIT Established Investigator.]
- 23 October 2020
- Published by SPIE-Intl Soc Optical Eng in Journal of Medical Imaging
- Vol. 7 (05) , 057002-12
Characterization of indeterminate breast lesions on B-mode ultrasound using automated machine learning models
Purpose: While mammography has excellent sensitivity for the detection of breast lesions, its specificity is limited. Adjunct screening with ultrasound may partially alleviate this issue but also increases false positives, resulting in unnecessary biopsies. Our study investigated the use of Google AutoML Vision (Mountain View, California), a commercially available machine learning service, to both identify and characterize indeterminate breast lesions on ultrasound. Approach: B-mode images from 253 independent cases of indeterminate breast lesions scheduled for core biopsy were used for model creation and validation. The performances of two sub-models from AutoML Vision, the image classification model and object detection model, were evaluated, while also investigating training strategies to enhance model performances. Pathology from the patient’s biopsy was used as a reference standard. Results: The image classification models trained under different conditions demonstrated areas under the precision–recall curve (AUC) ranging from 0.85 to 0.96 during internal validation. Once deployed, the model with highest internal performance demonstrated a sensitivity of 100% [95% confidence interval (CI) of 73.5% to 100%], specificity of 83.3% (CI = 51.6 % to 97.9%), positive predictive value (PPV) of 85.7% (CI = 62.9 % to 95.5%), and negative predictive value (NPV) of 100% (CI non-evaluable) in an independent dataset. The object detection model demonstrated lower performance internally during development (AUC = 0.67) and during prediction in the independent dataset [sensitivity = 75 % (CI = 42.8 to 94.5), specificity = 80 % (CI = 51.9 to 95.7), PPV = 75 % (CI = 50.8 to 90.0), and NPV = 80 % (CI = 59.3 % to 91.7%)], but was able to demonstrate the location of the lesion within the image. Conclusions: Two models appear to be useful tools for identifying and classifying suspicious areas on B-mode images of indeterminate breast lesions.
- 23 October 2020
- Published by SPIE-Intl Soc Optical Eng in Journal of Medical Imaging
- Vol. 7 (05) , 057002-12
Characterization of indeterminate breast lesions on B-mode ultrasound using automated machine learning models
Purpose: While mammography has excellent sensitivity for the detection of breast lesions, its specificity is limited. Adjunct screening with ultrasound may partially alleviate this issue but also increases false positives, resulting in unnecessary biopsies. Our study investigated the use of Google AutoML Vision (Mountain View, California), a commercially available machine learning service, to both identify and characterize indeterminate breast lesions on ultrasound. Approach: B-mode images from 253 independent cases of indeterminate breast lesions scheduled for core biopsy were used for model creation and validation. The performances of two sub-models from AutoML Vision, the image classification model and object detection model, were evaluated, while also investigating training strategies to enhance model performances. Pathology from the patient’s biopsy was used as a reference standard. Results: The image classification models trained under different conditions demonstrated areas under the precision–recall curve (AUC) ranging from 0.85 to 0.96 during internal validation. Once deployed, the model with highest internal performance demonstrated a sensitivity of 100% [95% confidence interval (CI) of 73.5% to 100%], specificity of 83.3% (CI = 51.6 % to 97.9%), positive predictive value (PPV) of 85.7% (CI = 62.9 % to 95.5%), and negative predictive value (NPV) of 100% (CI non-evaluable) in an independent dataset. The object detection model demonstrated lower performance internally during development (AUC = 0.67) and during prediction in the independent dataset [sensitivity = 75 % (CI = 42.8 to 94.5), specificity = 80 % (CI = 51.9 to 95.7), PPV = 75 % (CI = 50.8 to 90.0), and NPV = 80 % (CI = 59.3 % to 91.7%)], but was able to demonstrate the location of the lesion within the image. Conclusions: Two models appear to be useful tools for identifying and classifying suspicious areas on B-mode images of indeterminate breast lesions.
- 1 August 2020
- Published by Elsevier in Academic Radiology
- Vol. 27 (8) , 1065-1074
Characterizing Breast Lesions Using Quantitative Parametric 3D Subharmonic Imaging: A Multicenter Study
- 1 August 2020
- Published by Elsevier in Academic Radiology
- Vol. 27 (8) , 1065-1074
Characterizing Breast Lesions Using Quantitative Parametric 3D Subharmonic Imaging: A Multicenter Study
- 1 October 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1177-1180
Combining Quantitative 3D Subharmonic Imaging and Clinical Assessments for Accurate Characterization of Breast Masses
This multi-center study evaluated the ability of contrast-enhanced, nonlinear 3D ultrasound imaging to characterize indeterminate breast lesions using quantitative parametric maps and clinical assessments. In total 236 women with biopsy-proven breast lesions were enrolled in this study. Following B-mode and power Doppler imaging (PDI), an ultrasound contrast agent (Definity®, Lantheus Medical Imaging, N Billerica, MA, USA) was administrated. Contrast-enhanced 3D harmonic imaging (HI; transmitting/receiving at 5.0/10.0 MHz) as well as 3D subharmonic imaging (SHI; transmitting/receiving at 5.8/2.9 MHz) were performed using a modified Logiq 9 scanner (GE Healthcare, Waukesha, WI, USA) with a 4D10L probe. Five radiologists blinded to the reference independently scored the imaging modes using a 7-point BIRADS scale. Parametric volumes were constructed from time-intensity curves for vascular heterogeneity, perfusion (PER as the slope of the curve) and area under the curve (AUC) based on individual voxel values in the lesion. ROC analysis were applied to assess diagnostic accuracy with biopsy results as the reference. Out of the 236 cases, 219 were successfully scanned and biopsies resulted in 164 (75%) benign and 55 (25%) malignant lesions. 3D HI showed flow in 8 lesions (5 benign and 3 malignant), whereas 3D SHI visualized flow in 83 lesions (58 benign and 25 malignant). Hence, extracting quantitative parameters was restricted to the SHI volumes that demonstrated sufficient flow for processing. Diagnostic accuracy for the quantitative SHI parameters ranged from 0.52 to 0.75. Diagnostic accuracies from the clinical assessments ranged from 0.55-0.94 for baseline ultrasound, 0.52-0.93 for PDI, 0.59-0.85 for HI and 0.55-0.91 for SHI. The best logistical regression model achieved an accuracy of 0.91. In conclusion, combining quantitative SHI perfusion estimates and conventional B-mode imaging may increase the accuracy for characterizing indeterminate breast masses.
- 1 October 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1177-1180
Combining Quantitative 3D Subharmonic Imaging and Clinical Assessments for Accurate Characterization of Breast Masses
This multi-center study evaluated the ability of contrast-enhanced, nonlinear 3D ultrasound imaging to characterize indeterminate breast lesions using quantitative parametric maps and clinical assessments. In total 236 women with biopsy-proven breast lesions were enrolled in this study. Following B-mode and power Doppler imaging (PDI), an ultrasound contrast agent (Definity®, Lantheus Medical Imaging, N Billerica, MA, USA) was administrated. Contrast-enhanced 3D harmonic imaging (HI; transmitting/receiving at 5.0/10.0 MHz) as well as 3D subharmonic imaging (SHI; transmitting/receiving at 5.8/2.9 MHz) were performed using a modified Logiq 9 scanner (GE Healthcare, Waukesha, WI, USA) with a 4D10L probe. Five radiologists blinded to the reference independently scored the imaging modes using a 7-point BIRADS scale. Parametric volumes were constructed from time-intensity curves for vascular heterogeneity, perfusion (PER as the slope of the curve) and area under the curve (AUC) based on individual voxel values in the lesion. ROC analysis were applied to assess diagnostic accuracy with biopsy results as the reference. Out of the 236 cases, 219 were successfully scanned and biopsies resulted in 164 (75%) benign and 55 (25%) malignant lesions. 3D HI showed flow in 8 lesions (5 benign and 3 malignant), whereas 3D SHI visualized flow in 83 lesions (58 benign and 25 malignant). Hence, extracting quantitative parameters was restricted to the SHI volumes that demonstrated sufficient flow for processing. Diagnostic accuracy for the quantitative SHI parameters ranged from 0.52 to 0.75. Diagnostic accuracies from the clinical assessments ranged from 0.55-0.94 for baseline ultrasound, 0.52-0.93 for PDI, 0.59-0.85 for HI and 0.55-0.91 for SHI. The best logistical regression model achieved an accuracy of 0.91. In conclusion, combining quantitative SHI perfusion estimates and conventional B-mode imaging may increase the accuracy for characterizing indeterminate breast masses.
- 1 July 2019
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 213 (1) , W9-W16
Catalase-Containing Silica Particles as Ultrasound-Based Hydrogen Peroxide Sensors to Determine Infected From Noninfected Fluid Collections in Humans
OBJECTIVE. Hydrogen peroxide (H2O2) plays a key role in neutrophil oxidative defense against infection. Catalase-containing silica nanoshells are nanoparticles that generate O2 microbubbles imaged with ultrasound in the presence of elevated H2O2. We aimed to determine whether ultrasound-detectable O2 microbubbles produced by catalase-containing silica nanoshells can determine whether fluid collections drained from patients are infected. SUBJECTS AND METHODS. During this HIPAA-compliant, institutional review board–approved study, 52 human fluid samples were collected from clinically required image-guided percutaneous drainage procedures. Catalase-containing silica nanoshells were added to the fluid samples during imaging in real time using a Sequoia-512 15L8-S linear transducer (Siemens Healthcare). Production of detectable microbubbles was graded subjectively as negative (noninfected) or positive (infected) with low, moderate, or high confidence by a single observer blinded to all clinical data. The truth...
- 1 July 2019
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 213 (1) , W9-W16
Catalase-Containing Silica Particles as Ultrasound-Based Hydrogen Peroxide Sensors to Determine Infected From Noninfected Fluid Collections in Humans
OBJECTIVE. Hydrogen peroxide (H2O2) plays a key role in neutrophil oxidative defense against infection. Catalase-containing silica nanoshells are nanoparticles that generate O2 microbubbles imaged with ultrasound in the presence of elevated H2O2. We aimed to determine whether ultrasound-detectable O2 microbubbles produced by catalase-containing silica nanoshells can determine whether fluid collections drained from patients are infected. SUBJECTS AND METHODS. During this HIPAA-compliant, institutional review board–approved study, 52 human fluid samples were collected from clinically required image-guided percutaneous drainage procedures. Catalase-containing silica nanoshells were added to the fluid samples during imaging in real time using a Sequoia-512 15L8-S linear transducer (Siemens Healthcare). Production of detectable microbubbles was graded subjectively as negative (noninfected) or positive (infected) with low, moderate, or high confidence by a single observer blinded to all clinical data. The truth...
- 1 February 2019
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (2) , 492-504
Accomplishments and challenges in stem cell imaging in vivo
- 1 February 2019
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (2) , 492-504
Accomplishments and challenges in stem cell imaging in vivo
- 1 March 2018
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 286 (3) , 1062-1071
Focal Liver Lesions: Computer-aided Diagnosis by Using Contrast-enhanced US Cine Recordings
Computer-aided diagnosis systems accurately classified 11 different focal liver lesion types as benign or malignant by analyzing 3-minute contrast-enhanced US cine clips acquired as a dual display to automatically extract hallmark sonographic, enhancement, and time-intensity curve features. PurposeTo assess the performance of computer-aided diagnosis (CAD) systems and to determine the dominant ultrasonographic (US) features when classifying benign versus malignant focal liver lesions (FLLs) by using contrast material–enhanced US cine clips.Materials and MethodsOne hundred six US data sets in all subjects enrolled by three centers from a multicenter trial that included 54 malignant, 51 benign, and one indeterminate FLL were retrospectively analyzed. The 105 benign or malignant lesions were confirmed at histologic examination, contrast-enhanced computed tomography (CT), dynamic contrast-enhanced magnetic resonance (MR) imaging, and/or 6 or more months of clinical follow-up. Data sets included 3-minute cine clips that were automatically corrected for in-plane motion and automatically filtered out frames acquired off plane. B-mode and contrast-specific features were automatically extracted on a pixel-by-pixel basis and analyzed by using an artificial neural network (ANN) and a support vector mac...
- 1 March 2018
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 286 (3) , 1062-1071
Focal Liver Lesions: Computer-aided Diagnosis by Using Contrast-enhanced US Cine Recordings
Computer-aided diagnosis systems accurately classified 11 different focal liver lesion types as benign or malignant by analyzing 3-minute contrast-enhanced US cine clips acquired as a dual display to automatically extract hallmark sonographic, enhancement, and time-intensity curve features. PurposeTo assess the performance of computer-aided diagnosis (CAD) systems and to determine the dominant ultrasonographic (US) features when classifying benign versus malignant focal liver lesions (FLLs) by using contrast material–enhanced US cine clips.Materials and MethodsOne hundred six US data sets in all subjects enrolled by three centers from a multicenter trial that included 54 malignant, 51 benign, and one indeterminate FLL were retrospectively analyzed. The 105 benign or malignant lesions were confirmed at histologic examination, contrast-enhanced computed tomography (CT), dynamic contrast-enhanced magnetic resonance (MR) imaging, and/or 6 or more months of clinical follow-up. Data sets included 3-minute cine clips that were automatically corrected for in-plane motion and automatically filtered out frames acquired off plane. B-mode and contrast-specific features were automatically extracted on a pixel-by-pixel basis and analyzed by using an artificial neural network (ANN) and a support vector mac...
- 20 October 2017
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 9 (43) , 37587-37596
Thrombin-Activatable Microbubbles as Potential Ultrasound Contrast Agents for the Detection of Acute Thrombosis
Acute deep vein thrombosis (DVT) is the formation of a blood clot in the deep veins of the body that can lead to fatal pulmonary embolism. Acute DVT is difficult to distinguish from chronic DVT by ultrasound (US), the imaging modality of choice, and is therefore treated aggressively with anticoagulants, which can lead to internal bleeding. Here we demonstrate that conjugating perfluorobutane-filled (PFB-filled) microbubbles (MBs) with thrombin-sensitive activatable cell-penetrating peptides (ACPPs) could lead to the development of contrast agents that detect acute thrombosis with US imaging. Successful conjugation of ACPP to PFB-filled MBs was confirmed by fluorescence microscopy and flow cytometry. Fluorescein-labeled ACPP was used to evaluate the efficiency of thrombin-triggered cleavage by measuring the mean fluorescence intensity of ACPP-labeled MBs (ACPP-MBs) before and after incubation at 37 °C with thrombin. Lastly, control MBs and ACPP-MBs were infused through a tube containing a clot, and US contrast enhancement was measured with or without the presence of a thrombin inhibitor after washing the clot with saline. With thrombin activity, 91.7 ± 14.2% of the signal was retained after ACPP-MB infusion and washing, whereas only 16.7 ± 4% of the signal was retained when infusing ACPP-MBs in the presence of hirudin, a potent thrombin inhibitor.
- 20 October 2017
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 9 (43) , 37587-37596
Thrombin-Activatable Microbubbles as Potential Ultrasound Contrast Agents for the Detection of Acute Thrombosis
Acute deep vein thrombosis (DVT) is the formation of a blood clot in the deep veins of the body that can lead to fatal pulmonary embolism. Acute DVT is difficult to distinguish from chronic DVT by ultrasound (US), the imaging modality of choice, and is therefore treated aggressively with anticoagulants, which can lead to internal bleeding. Here we demonstrate that conjugating perfluorobutane-filled (PFB-filled) microbubbles (MBs) with thrombin-sensitive activatable cell-penetrating peptides (ACPPs) could lead to the development of contrast agents that detect acute thrombosis with US imaging. Successful conjugation of ACPP to PFB-filled MBs was confirmed by fluorescence microscopy and flow cytometry. Fluorescein-labeled ACPP was used to evaluate the efficiency of thrombin-triggered cleavage by measuring the mean fluorescence intensity of ACPP-labeled MBs (ACPP-MBs) before and after incubation at 37 °C with thrombin. Lastly, control MBs and ACPP-MBs were infused through a tube containing a clot, and US contrast enhancement was measured with or without the presence of a thrombin inhibitor after washing the clot with saline. With thrombin activity, 91.7 ± 14.2% of the signal was retained after ACPP-MB infusion and washing, whereas only 16.7 ± 4% of the signal was retained when infusing ACPP-MBs in the presence of hirudin, a potent thrombin inhibitor.